Pd 173074 95.0%(HPLC)
95.0%(HPLC)
Properties
| Assay Purity | >95%(HPLC) |
| Refractive index | 1.598 |
| M pt. | 86℃ |
| Density | 1.163g/cm3 |
Safety Information
| Hazard Statement(s) | H319-H315 |
| Precautionary Statement | P264+P302 + P352+ P280+P337 + P313 +P305 + P351 + P338+ P362 + P364+ P332 |
| Symbol |
|
| Signal word | Warning |
| Storage Temp. | Store at 0-10℃ |
| Packaging | Glass bottle |
Description
Recommended products
1-(tert-Butyl)-3-[7-[[4-(diethylamino)butyl]amino]-3-(35-dimethoxyphenyl)pyrido[23-d]pyrimidin-2-yl]urea
Application
PD 173074 has been used to treat epithelial-mesenchymal transition (EMT)-induced cell lines in order to study its therapeutic use for head and neck squamous cell carcinoma (HNSCC) in combination with PD0325901 to test whether an alternative downstream pathway for (fibroblast growth factor) FGF signalling is adopted during human hypoblast induction to study its potential role in acute lymphoblastic leukaemia (ALL)-derived cell lines (TOM-1 and NALM-20)
General Description
PD 173074 is a selective FGFR1 and FGFR3 inhibitor. PD 173074 is a compound induced a dose-dependent reduce in cell viability and an increase in apoptosis accompanied by a decrease in extracellular signal-related kinase phosphorylation.
Documents
| SDS | |
| COA | |
| Specification | |
| Bulk quote order form |